Evogene Financial Statements From 2010 to 2025

EVGN Stock  USD 1.78  0.17  10.56%   
Evogene financial statements provide useful quarterly and yearly information to potential Evogene investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Evogene financial statements helps investors assess Evogene's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Evogene's valuation are summarized below:
Gross Profit
7.7 M
Profit Margin
(2.10)
Market Capitalization
11.6 M
Enterprise Value Revenue
0.226
Revenue
9.4 M
We have found one hundred twenty available fundamental signals for Evogene, which can be analyzed and compared to other ratios and to its rivals. Self-guided Investors are advised to verify Evogene's prevailing fundamentals against the trend between 2010 and 2025 to make sure the company can sustain itself down the road. As of the 21st of January 2025, Market Cap is likely to drop to about 411.7 M. In addition to that, Enterprise Value is likely to drop to about 401.6 M

Evogene Total Revenue

5.96 Million

Check Evogene financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Evogene's main balance sheet or income statement drivers, such as Depreciation And Amortization of 2.8 M, Interest Expense of 186.8 K or Selling General Administrative of 5.2 M, as well as many indicators such as Price To Sales Ratio of 72.99, Dividend Yield of 0.0 or PTB Ratio of 34.16. Evogene financial statements analysis is a perfect complement when working with Evogene Valuation or Volatility modules.
  
Check out the analysis of Evogene Correlation against competitors.
To learn how to invest in Evogene Stock, please use our How to Invest in Evogene guide.

Evogene Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets65 M46 M78 M
Slightly volatile
Common Stock Shares Outstanding3.9 M4.1 M16.9 M
Slightly volatile
Other Current Liabilities2.8 M4.5 MM
Pretty Stable
Total Current Liabilities5.6 M6.2 MM
Slightly volatile
Total Stockholder Equity10.3 M10.8 M56.7 M
Slightly volatile
Other Liabilities17.8 M17 M7.8 M
Slightly volatile
Accounts Payable1.2 M1.6 M1.5 M
Slightly volatile
Cash26.8 M23.9 M23.4 M
Pretty Stable
Other Assets1.091.1529.5 K
Pretty Stable
Short Term Investments8.8 M9.3 M40 M
Slightly volatile
Other Current Assets2.3 M2.4 M5.4 M
Pretty Stable
Total Liabilities15 M25.8 M14.9 M
Pretty Stable
Intangible Assets10.4 M15.1 M11.7 M
Slightly volatile
Common Stock181.2 K328.9 K171.9 K
Slightly volatile
Property Plant Equipment4.7 M3.7 M5.6 M
Slightly volatile
Property Plant And Equipment Net4.5 M3.1 M5.6 M
Slightly volatile
Current Deferred Revenue309.5 K325.8 K1.6 M
Slightly volatile
Non Current Assets Total13.2 M19.1 M12 M
Slightly volatile
Non Currrent Assets Other28.4 K32.2 K28.5 K
Very volatile
Cash And Short Term Investments55.2 M28 M63.8 M
Slightly volatile
Net Receivables573.7 K603.9 K1.5 M
Slightly volatile
Common Stock Total Equity157.2 K230 K154.8 K
Slightly volatile
Liabilities And Stockholders Equity66.8 M46 M77.7 M
Slightly volatile
Non Current Liabilities Total18.7 M17.8 M7.9 M
Slightly volatile
Other Stockholder Equity225.1 M309.8 M198.1 M
Slightly volatile
Property Plant And Equipment Gross31.4 M29.9 M10.4 M
Slightly volatile
Total Current Assets57.2 M31 M66.3 M
Slightly volatile
Short Term Debt729.3 K767.7 KM
Slightly volatile
Net Tangible Assets11.8 M12.4 M67.4 M
Slightly volatile
Long Term Investments341.2 K343.8 K399.3 K
Slightly volatile
Deferred Long Term Liabilities76.1 K80.1 K217.5 K
Slightly volatile
Short and Long Term Debt2.5 M2.6 M3.2 M
Slightly volatile
Capital Surpluse207.6 M236.8 M194.5 M
Slightly volatile
Non Current Liabilities Other3.7 M4.2 M3.5 M
Slightly volatile
Net Invested Capital37.7 M20.2 M54.6 M
Slightly volatile
Net Working Capital35.8 M24.8 M53.2 M
Slightly volatile
Capital Stock227.2 K328.9 K183.2 K
Slightly volatile
Short and Long Term Debt Total6.9 M13.2 M4.9 M
Slightly volatile
Long Term Debt Total1.7 M1.9 MM
Slightly volatile
Capital Lease Obligations1.8 MM2.5 M
Slightly volatile
Long Term Debt11.3 M11.9 M10.3 M
Slightly volatile

Evogene Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization2.8 MM2.5 M
Slightly volatile
Interest Expense186.8 K196.7 K1.1 M
Pretty Stable
Selling General Administrative5.2 M10 MM
Slightly volatile
Total RevenueM5.1 M7.7 M
Slightly volatile
Gross Profit2.1 M1.3 M2.8 M
Slightly volatile
Other Operating Expenses28.6 M36.8 M26.4 M
Slightly volatile
Research Development18 M20.8 M16.1 M
Slightly volatile
Cost Of Revenue3.9 M3.8 M4.9 M
Slightly volatile
Total Operating Expenses23.3 M32 M21.3 M
Slightly volatile
Interest Income1.1 M567.9 K1.3 M
Slightly volatile
Minority Interest3.7 M2.5 M2.3 M
Slightly volatile
Tax Provision34.6 K18.4 K32.6 K
Very volatile
Reconciled Depreciation2.7 MM2.4 M
Slightly volatile
Selling And Marketing Expenses1.7 M1.2 M885 K
Slightly volatile

Evogene Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based CompensationM1.7 M2.4 M
Pretty Stable
Begin Period Cash Flow25.9 M33.3 M23.5 M
Pretty Stable
Depreciation2.5 MM2.3 M
Slightly volatile
Capital Expenditures1.2 M706.5 K1.6 M
Slightly volatile
Total Cash From Financing Activities12.2 M16.3 M15.7 M
Pretty Stable
End Period Cash Flow26.8 M23.9 M23.4 M
Pretty Stable
Sale Purchase Of Stock10.7 MM24.5 M
Slightly volatile
Issuance Of Capital Stock10.7 M7.6 M10.9 M
Very volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio72.9976.844.2 K
Slightly volatile
PTB Ratio34.1635.95191
Very volatile
Days Sales Outstanding19.7520.79168
Pretty Stable
Book Value Per Share0.690.722.5032
Slightly volatile
Stock Based Compensation To Revenue0.280.30.8556
Slightly volatile
Capex To Depreciation0.330.350.8287
Slightly volatile
PB Ratio34.1635.95191
Very volatile
EV To Sales71.274.95K
Very volatile
Payables Turnover1.041.093.0329
Slightly volatile
Sales General And Administrative To Revenue1.530.971.9223
Slightly volatile
Research And Ddevelopement To Revenue6.563.327.3094
Slightly volatile
Capex To Revenue0.120.130.3391
Pretty Stable
Cash Per Share0.740.782.5345
Slightly volatile
Days Payables Outstanding260347289
Slightly volatile
Income Quality1.030.961.0914
Slightly volatile
Intangibles To Total Assets0.140.230.1715
Slightly volatile
Net Debt To EBITDA0.440.464.9386
Slightly volatile
Current Ratio5.425.719.6629
Slightly volatile
Tangible Book Value Per Share0.370.392.3213
Slightly volatile
Receivables Turnover19.0818.177.4598
Pretty Stable
Graham Number1.922.034.9069
Slightly volatile
Shareholders Equity Per Share0.290.32.3552
Slightly volatile
Debt To Equity0.90.860.2398
Slightly volatile
Capex Per Share0.01880.01980.0705
Slightly volatile
Graham Net Net0.210.231.7864
Slightly volatile
Revenue Per Share0.130.140.3468
Slightly volatile
Interest Debt Per Share0.240.230.1184
Slightly volatile
Debt To Assets0.210.20.0833
Slightly volatile
Price Book Value Ratio34.1635.95191
Very volatile
Days Of Payables Outstanding260347289
Slightly volatile
Company Equity Multiplier4.013.821.824
Slightly volatile
Long Term Debt To Capitalization0.290.420.2893
Slightly volatile
Total Debt To Capitalization0.460.440.1465
Slightly volatile
Debt Equity Ratio0.90.860.2398
Slightly volatile
Quick Ratio5.415.711.0218
Slightly volatile
Net Income Per E B T1.11.061.0114
Very volatile
Cash Ratio2.822.693.3053
Very volatile
Days Of Sales Outstanding19.7520.79168
Pretty Stable
Price To Book Ratio34.1635.95191
Very volatile
Fixed Asset Turnover1.171.891.2729
Slightly volatile
Debt Ratio0.210.20.0833
Slightly volatile
Price Sales Ratio72.9976.844.2 K
Slightly volatile
Asset Turnover0.08460.130.104
Slightly volatile
Gross Profit Margin0.660.630.4025
Slightly volatile
Price Fair Value34.1635.95191
Very volatile

Evogene Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap411.7 M433.4 M32.2 B
Slightly volatile
Enterprise Value401.6 M422.7 M14.5 B
Pretty Stable

Evogene Fundamental Market Drivers

Cash And Short Term Investments31.1 M

Evogene Upcoming Events

14th of March 2024
Upcoming Quarterly Report
View
16th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
14th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Evogene Financial Statements

Evogene investors utilize fundamental indicators, such as revenue or net income, to predict how Evogene Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue325.8 K309.5 K
Total Revenue5.1 MM
Cost Of Revenue3.8 M3.9 M
Stock Based Compensation To Revenue 0.30  0.28 
Sales General And Administrative To Revenue 0.97  1.53 
Research And Ddevelopement To Revenue 3.32  6.56 
Capex To Revenue 0.13  0.12 
Revenue Per Share 0.14  0.13 
Ebit Per Revenue(5.40)(5.68)

Pair Trading with Evogene

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Evogene position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Evogene will appreciate offsetting losses from the drop in the long position's value.

Moving together with Evogene Stock

  0.8AZN AstraZeneca PLC ADRPairCorr
  0.82GSK GlaxoSmithKline PLC ADR Sell-off TrendPairCorr
  0.65MRK Merck Company Fiscal Year End 6th of February 2025 PairCorr
  0.85NVS Novartis AG ADRPairCorr
  0.84PFE Pfizer Inc Earnings Call This WeekPairCorr

Moving against Evogene Stock

  0.72MBFJF Mitsubishi UFJ FinancialPairCorr
  0.63GILD Gilead SciencesPairCorr
  0.57LH LaboratoryPairCorr
The ability to find closely correlated positions to Evogene could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Evogene when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Evogene - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Evogene to buy it.
The correlation of Evogene is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Evogene moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Evogene moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Evogene can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Evogene offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Evogene's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Evogene Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Evogene Stock:
Check out the analysis of Evogene Correlation against competitors.
To learn how to invest in Evogene Stock, please use our How to Invest in Evogene guide.
You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Evogene. If investors know Evogene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Evogene listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(4.46)
Revenue Per Share
1.881
Quarterly Revenue Growth
0.398
Return On Assets
(0.28)
Return On Equity
(0.82)
The market value of Evogene is measured differently than its book value, which is the value of Evogene that is recorded on the company's balance sheet. Investors also form their own opinion of Evogene's value that differs from its market value or its book value, called intrinsic value, which is Evogene's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Evogene's market value can be influenced by many factors that don't directly affect Evogene's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Evogene's value and its price as these two are different measures arrived at by different means. Investors typically determine if Evogene is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Evogene's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.